Mesenchymal Stem Cell Culture for ALS Neuromuscular Junction Repair
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Amyotrophic Lateral Sclerosis (ALS) are ineffective, and there is a need for a reliable source of therapeutic stem cells that can ameliorate denervation at neuromuscular junctions caused by the disease.
Innovation Solution
The production of non-genetically modified human mesenchymal stem cells (MSCs) that are activated ex vivo to secrete increased levels of laminin β2, GDNF, BDNF, and VEGF, using a cell culture composition including Insulin-like growth factor 1 (IGF-1), which are then administered to ALS model mice to improve neuromuscular junction denervation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional cell culture conditions are used to maintain MSCs, then cell viability and basic function are preserved, but the secretion of neurotrophic factors and synaptic organizing agents (laminin β2, GDNF, BDNF, VEGF) is insufficient for therapeutic effect
Solution Approach 1:
The patent modifies cell culture parameters by adding specific growth factors (IGF-1, FGF-2, EGF, PDGF) and adjusting culture conditions (serum-free media, controlled pH, temperature) to stimulate MSCs to secrete higher levels of therapeutic proteins. This resolves the contradiction by changing cultural parameters to increase substance secretion without requiring complex genetic modification protocols.
Solution Approach 2:
The patent uses growth factors (IGF-1, FGF-2, EGF, PDGF) as intermediary substances that mediate between the culture media and MSCs, triggering the cells to produce and secrete therapeutic proteins. These intermediaries act as signals that bridge the gap between basic cell maintenance and therapeutic substance production.
2Reliability
If MSCs are activated ex vivo to increase therapeutic factor secretion, then therapeutic efficacy is improved, but the complexity of cell activation protocols increases
Solution Approach 1:
The patent performs cell activation protocols ex vivo before administration to patients, pre-stimulating MSCs with growth factors in controlled culture conditions. This preliminary action ensures that cells are optimized for therapeutic effect before being introduced to the patient, improving reliability while containing complexity in a controlled pre-treatment phase rather than during patient treatment.
Solution Approach 2:
The patent utilizes controlled changes in culture parameters (addition of specific growth factors, serum-free conditions, controlled pH and temperature) to activate MSCs ex vivo. These parameter changes provide a reliable and controllable method to enhance therapeutic secretion without requiring complex genetic engineering or multi-step protocols.
3Ease of manufacture
If non-genetically modified MSCs are used, then safety and ease of production are improved, but the ability to consistently produce high levels of therapeutic factors is limited
Solution Approach 1:
The patent achieves consistent high-level secretion of therapeutic factors from non-genetically modified MSCs by optimizing cell culture parameters. By controlling media composition (adding IGF-1, FGF-2, EGF, PDGF), pH, temperature, and serum-free conditions, the patent achieves reproducible and consistent production of laminin β2, GDNF, BDNF, and VEGF without genetic modification, maintaining ease of manufacture while ensuring consistent substance quantity.
Solution Approach 2:
The patent employs growth factors (IGF-1, FGF-2, EGF, PDGF) as intermediary substances that consistently trigger MSCs to produce therapeutic factors. These intermediaries serve as reliable signals that can be added to culture media to ensure consistent and reproducible secretion levels from non-modified cells, bridging the gap between production simplicity and consistent high-level output.
Data Source
AI summary
Embodiments of the present disclosure relate generally to the production of therapeutic mesenchymal stem cells (MSCs). More particularly, the present disclosure relates to the use of cell culture compositions and methods for generating MSCs that secrete neurotrophic factors and synaptic organizing agents for the treatment of neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS). As such, the present disclosure addresses the need for establishing a reliable source of therapeutic stem cells useful for the treatment of neurodegenerative diseases.